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Increased plasma concentrations of LDL-unbound apo(a) in patients
with end-stage renal disease. Rapid Communication. Lipoprotein(a)
[Lp(a)] and its characteristic glycoprotein apolipoprotein(a) [apo(a)I are
risk factors for atherosclerosis in the general population. Patients with
renal disease show an elevation of Lp(a). Recent studies have described an
arteriovenous difference of Lp(a) in the renovascular bed as well as the
plasma-derived fragmented LDL-unbound apo(a) in urine, suggesting that
the kidney is involved in the metabolism of Lp(a). We therefore investi-
gated whether patients with chronic renal failure have higher levels of
LDL-unbound apo(a) and whether this could account for the increased
Lp(a) concentrations in these patients. In addition, we studied the possible
generation of apo(a) fragments in vitro by mimicking uremic plasma
conditions and by investigating the assembly of Lp(a) in cell culture
experiments. Patients treated by hemodialysis (N = 185) and by continu-
ous ambulatory peritoneal dialysis (CAPD; N = 20) had markedly
elevated absolute (1.22 1.55 mg/dl and 2.14 2.86 mgldl) as well as
relative (7.5% and 7.3%) amounts of LDL-unbound apo(a) in comparison
to controls (0.46 0.48 mg/dl or 4.5%). Following renal transplantation
the absolute amount decreased significantly. Lp(a) plasma concentration
was the most important determining variable for the absolute amount of
LDL-unbound apo(a) and showed a positive correlation in both hemodi-
alysis patients (r = 0.85) and controls (r 0.92). In vitro experiments
demonstrated that "uremization" of plasma samples did not generate a
higher amount of LDL-unbound apo(a). Although LDL of renal patients
has different chemical and structural properties as compared to control
LDL, the extracellular assembly of Lp(a) did not differ between patients
and controls. Therefore, the higher amounts of LDL-unbound apo(a)
found in renal disease are not caused by an impaired assembly of Lp(a),
but rather indicate a catabolic role of the kidney for LDL-unbound apo(a)
as was already shown for Lp(a). Despite a small contribution, these
elevated levels cannot explain the higher Lp(a) values found in patients
with end-stage renal disease.
Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein and
the highly polymorphic glycoprotein apolipoprotein(a) [apo(a)].
The concentrations of Lp(a) are mainly determined by the size
polymorphism of apo(a) [1] that is caused by a varying number of
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kringle-IV (K-Tv) repeats in the apo(a) gene [2—4]. Subjects with
a low number of K-TV repeats usually have a high concentration
of Lp(a) and those with a high number of K-IV repeats express
low concentrations. Several retrospective and prospective studies
have shown an association between high Lp(a) plasma concentra-
tions and coronary heart disease [reviewed in 5, 6].
During recent years several studies have described elevated
plasma concentrations of Lp(a) in patients with renal disease (for
review, see reference [7]). The pronounced risk for atherosclerotic
complications in these patients [8] was found to be related to the
Lp(a) concentrations and/or apo(a) phenotypes [9—13].
The finding of elevated Lp(a) concentrations in renal patients
together with a decrease in Lp(a) following successful renal
transplantation [14, 15] suggested a role of the kidney in the
metabolism of Lp(a). This role is supported by apo(a) fragments
of various sizes found in urine of healthy subjects [16—181 and by
arteriovenous differences in Lp(a) concentrations between the
aorta and the renal vein with lower values in the renal vein [19].
Furthermore, plasma apo(a) fragments larger in size than urinary
fragments have been described. Intravenous injection of these
purified plasma fragments into mice, a species that does not
produce apo(a), resulted in the detection of smaller fragments in
mouse urine that were similar to those found in human urine [20].
Thus, if the plasma apo(a) fragments are the source of the
(smaller) urinary fragments, patients with chronic renal failure
would be expected to have higher levels of LDL-unbound apo(a).
In this study we therefore investigated whether patients with
end-stage renal disease have elevated concentrations of plasma
apo(a) fragments in comparison to controls and, if so, whether
this could account for the increased Lp(a) concentrations in these
patients. In addition, we studied the possible generation of apo(a)
fragments in vitro, first, by mimicking uremic plasma conditions
and second, by investigating the assembly of Lp(a) in cell culture
experiments. These experiments aimed to demonstrate whether
elevated Lp(a) concentrations or apo(a) fragments in hemodial-
ysis patients are related to changes in the assembly of Lp(a). It has
been shown that Lp(a) is assembled extracellularly or at the
plasma membrane from preformed apo(a) and LDL [21—23]. We
therefore incubated purified LDL from hemodialysis patients and
controls with recombinant human apo(a) obtained from stably
transfected cells.
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METHODS
Patients and procedure of blood sampling
A total of 185 hemodialysis patients and 163 healthy blood
donors were included in this study. The patient group consisted of
100 men and 85 women with a mean age of 54 15 years. At the
time of blood withdrawal they had been undergoing hemodialysis
for an average of 35 32 (range 2 to 170) months. Treatment was
performed three times weekly for an average of four hours. The
cause of chronic renal failure was chronic glomerulonephritis in
70 (38%), diabetic nephropathy in 28 (15%), chronic pyelonephri-
tis in 20 (11%), polycystic kidney disease in 17 (9%), renovascular
disease in 13 (7%), analgesic nephropathy in seven (4%) and
other diseases in seven cases (4%), while the origin was unknown
in 23 (12%) cases. Moreover, a group of 20 patients treated by
continuous ambulatory peritoneal dialysis (CAPD) was also in-
vestigated (mean age 58 16 years). The control group included
100 men and 63 women with a mean age of 36 12 years.
Furthermore, the amount of LDL-unbound apo(a) was deter-
mined immediately before and four weeks after successful renal
transplantation in 19 hemodialysis patients (mean age 44 31
years). Postoperative immunosuppressive therapy consisted of a
triple-drug regimen (combination of cyclosporine A, azathioprine
and prednisone) in 17 patients. Two patients were treated with a
double-drug therapy (azathioprine and prednisone). Detailed
information about the postoperative immunosuppressive therapy
is described elsewhere [15].
Assembly experiments in cell culture
We used human embryonic kidney cells (293T) stably trans-
fected with an apo(a) expression vector containing 18 kringle-IV
repeats as described in detail elsewhere [221. These cells secrete
only recombinant apo(a) [r-apo(a)] but no other lipoproteins.
Lp(a) was extracellularly assembled by adding purified LDL from
hemodialysis patients or controls to the medium. Confluent cells
(N = 1.6 x 106/ml) were incubated in six-well plates for 16 hours
at 37°C in DMEM (Dulbecco's minimum essential medium, High
Glucose) from Boehringer Mannheim, Germany. Thereafter, the
medium was replaced with 2 ml of new medium containing 50 or
200 tg/ml LDL protein. After 30, 60, 90 and 120 minutes, 100 d
of medium was taken and analyzed by 6.6% SDS-PAGE under
non-reducing conditions followed by immunoblotting. Apo(a)-
specific immunodetection was performed with the monoclonal
antibody 1A2 [24] and the enhanced chemiluminescence Western
blot detection kit (Amersham Buehler GmBH, Braunschweig,
Germany). The relative intensities of the bands corresponding to
r-apo(a) and assembled Lp(a) [r-apo(a)-apoB complex] were
determined by densiometry using a Personal Densitometer SI
(Molecular Dynamics, USA). Increasing the duration of the
incubation period did not result in a higher amount of assembled
Lp(a) complex in experiments using LDL from patients as well as
from controls. Since the addition of 200 ig/ml LDL to the
medium affected neither the kinetics of the assembly of r-apo(a)
with LDL nor the amount of assembled Lp(a)-complex, we used
50 .ig/ml LDL protein for all further experiments.
LDL used in these assembly experiments was purified by
sequential preparative ultracentrifugation using plasma from he-
modialysis patients and controls with Lp(a) concentrations < 3
mgldl. Briefly, VLDL and chylomicrons were removed from
plasma by ultracentrifugation at plasma density for 18 hours at
10°C and 39 000 r.p.m. in a 50.3 Ti rotor (Beckmann Instruments,
Paolo Alto, CA, USA). The infranatant was adjusted to d = 1.063
g/ml by addition of solid potassium bromide and spun for 24 hours
at 10°C and 49.000 r.p.m. in the same rotor. The floating material
containing LDL was obtained by aspiration followed by dialyza-
tion against phosphate-buffered saline. With this procedure it was
possible to obtain apo(a)-free LDL, which was verified in a 6.6%
SDS-PAGE under non-reducing conditions followed by silver
staining as well as measurement of Lp(a) by an ELISA described
below. All preparations were performed under nitrogen and in the
presence of 0.5 mg/mL EDTA to avoid oxidation of LDL.
Laboratory procedures
EDTA plasma was taken from patients after a 12-hour over-
night fast before dialysis. After low-speed centrifugation, samples
were frozen and kept at —80°C prior to analysis [25].
Lp(a) quantification was performed with a double-antibody
ELISA using an affinity-purified polyclonal rabbit anti-apo(a)
antibody for coating and the horseradish peroxidase-conjugated
monoclonal antibody 1A2 for detection [25]. This antibody does
not cross react with plasminogen and recognizes an epitope of the
repetitive K-IV motif of apo(a) [24]. Lp(a) positive serum from
Immuno (Vienna, Austria) served as standard. We estimated the
amount of "free" apo(a) that was not bound to apoB-100 in an
Lp(a) complex and that consisted mostly of apo(a) degradation
products [20] by the following procedure: 50 d of plasma were
incubated with 100 1id apoB-antiserum on a rotating disc for 16
hours at 4°C. After centrifugation for 10 minutes in an Eppendorf
high-speed centrifuge, apo(a) was measured in the supernatant by
the same ELISA procedure described above, yielding the amount
of free apo(a). We determined the amount of apoB-antiserum
necessary for a sufficient precipitation of LDL-containing parti-
cles by adding increasing amounts of this antiserum to plasma
samples with high concentrations of Lp(a) and LDL. To rule out
insufficient Lp(a) precipitation, apoB was generally monitored in
parallel to apo(a) in each supernatant by a double-antibody
ELISA. This ELISA uses the same affinity-purified polyclonal
antibody against apo B for coating and in a peroxidase-labeled
form for detection [26]. The relative amount of LDL-unbound
apo(a) was calculated with the formula
apo(a) in the supernatant * 100% LDL-unbound apo(a) =
Lp(a) plasma concentration
Plasma concentrations of apoA-IV were measured with the
ELISA technique as previously described [27]. Total and HDL
cholesterol were determined using kits from Boehringer Mann-
heim (Mannheim, Germany). Measurements were made on mi-
crotiter plates as previously described [25].
We partially "uremized" plasma samples from seven healthy
probands by adding the same amount of plasma from a hemodi-
alysis patient with only 0.03 mg/ill of Lp(a) plasma concentration
and a plasma creatinine of 10.2 mg/dl. This mixture was incubated
on a rotating disc for 24 hours at 4°C. Thereafter, the amount of
LDL-unbound apo(a) was determined in the original as well as in
the uremized plasma samples.
Apo(a) phenotyping was performed by sodium dodecyl sulfate-
agarose (SDS agarose) gel electrophoresis under reducing condi-
tions as outlined [28] with slight modifications, followed by
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Table 1. Comparison of mean SD plasma lipoproteins and
apolipoproteins in controls and hemodialysis patients
Controls
N=163
HD
N=185 P
Total cholesterol mg/dl 199 38 182 50 <0001
HDL cholesterol mg/dl 51.0 13.1 35.7 15.5 <0.001
Apo B mg/dl 108 26 102 34 = 0.06
Apo A-TV mg/dl 14.9 3.5 30.4 7.7 <0.001
Lp(a) mg/dl 18.2 20.9 25.2 28.0 <0.01
LDL-unbound apo(a) mg/dl 0.46 0.48 1.22 1.55 <0.001
LDL-unbound apo(a) % 4.5 3.9 7.5 7.2 <0.001
immunoblotting [1] using the monoclonal antibody 1A2 for the
detection of apo(a) phenotypes.
Statistical analysis
An unpaired t-test was used to compare normally distributed
variables between patients and controls. For non-normally distrib-
uted variables [Lp(a), absolute and relative amount of LDL-
unbound apo(a)1 the nonparametric Wilcoxon rank sum test was
applied. Spearman's rank correlation coefficients were calculated
between plasma concentrations of Lp(a), absolute and relative
LDL-unbound apo(a) and the number of K-TV repeats of the
smaller apo(a) band.
Because of the high number of detectable apo(a) isoforms (>
30), many phenotypes were represented only in low numbers. To
account for this problem, we decided a priori to combine apo(a)
isoforms in steps of three K-IV repeats according to the molecular
weight of the smaller apo(a) isoforms to obtain sufficient sample
sizes in each category [291. Since subjects with 11 to 16 or > 34
K-IV repeats were represented relatively rarely, we built one
group by combining 11 to 19 and one by combining > 31 K-TV
repeats. Patients were divided into six apo(a) isoform groups
according to this procedure. When two apo(a) isoforms were
detectable, we used only the smaller apo(a) isoform for categori-
zation, as done in previous works by us and others [10, 26, 30—331.
A one-way ANOVA analysis was used to compare the absolute
and relative amount of LDL-unbound apo(a) between the six
different apo(a) isoform groups, separately for patients and
controls.
We examined the influence of age, sex, group (hemodialysis
patients/controls), plasma concentrations of Lp(a), total and HDL
cholesterol, apoB, ApoA-IV and the number of K-IV repeats of
the smaller apo(a) isoform on the absolute amount of free apo(a)
by stepwise regression analysis. Statistical procedures were per-
formed with SPSS for Windows 6.1.3. A P value < 0.05 was
considered significant.
RESULTS
Fig. 1. Absolute (A) and relative (B) amount of LDL-unbound apo(a) as
well as Lp(a) plasma (C) concentrations (mean SEM) in 185 hemodi-
alysis patients and 163 controls in relation to the number of kringle IV
(K-IV) repeats. N is the number of controls (L) and patients (U) in each
K-TV repeat group.
in vivo findings
Table 1 shows lipoproteins, apolipoproteins and LDL-unbound
apo(a) of hemodialysis patients and controls. Hemodialysis pa-
tients had significantly higher Lp(a) plasma concentrations when
compared to controls. Although we observed a trend to higher
Lp(a) concentrations in all apo(a) isoform groups, this elevation
of Lp(a) reached only statistical significance in patients with high
molecular weight apo(a) phenotypes (Fig. 1). This is in accor-
dance with our previous works [26, 32]. Additionally, we found in
patients markedly elevated absolute (1.22 1.55 mg/dl vs. 0.46
0.48 mg/dl, P < 0.001) as well as relative (7.5 7.2% vs. 4.5
3.9%, P < 0.001) amounts of LDL-unbound apo(a) in comparison
to controls (Table 1). The absolute amount of LDL-unbound
apo(a) decreased significantly with the increasing number of K-IV
repeats for both hemodialysis patients and controls (P < 0.001 by
one-way ANOVA). In patients the concentration of LDL-un-
bound apo(a) was at least two times higher in each apo(a) isoform
group when compared to controls (Fig. 1). In contrast to the
absolute amount of LDL-unbound apo(a), the relative amount
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Fig. 2. Correlation between plasma concentrations of Lp(a) and LDL-
unbound apo(a) in hemodialysis patients (A; N = 185, r = 0.85, P <
0.001) and controls (B; N = 163, r = 0.92, P < 0.001).
increased with the number of K-TV repeats in patients and
controls (P < 0.05 and P < 0.001, respectively, by one-way
ANOVA) and was also higher in each of the apo(a) isoform
groups of patients (Fig. 1).
Lp(a) plasma concentrations correlated positively with the
absolute amount of LDL-unbound apo(a) in both groups (con-
trols r = 0.92, hemodialysis patients r = 0.85, P < 0.001 for both;
Fig. 2). A negative correlation was observed between the Lp(a)
plasma concentrations and the relative amount of LDL-unbound
apo(a) (controls r = —0.74, patients r = —0.60, P < 0.001 for
both). When we subgrouped patients and controls by the median
Lp(a) level of the control group (93 mg/dl), we observed in both
patients and controls higher relative amounts of LDL-unbound
apo(a) in those subjects with the lower in comparison to those
Variable Coefficient SE P
In Lp(a) 0.6366 0.0305 <0.0001
Patients/controls —2.1049 0.1233 <0.0001
HDL cholesterol 0.0051 0.0024 <0.05
with the higher Lp(a) plasma concentrations: controls 6.6% versus
2.3%, P < 0.001; patients 11.9% versus 4.5%, P < 0.001.
Stepwise regression analysis revealed the Lp(a) plasma concen-
tration to be the most important determining variable for the
amount of LDL-unbound apo(a) (P < 0.001) followed by the
grouping variable (patient/control; P < 0.001) and the concentra-
tion of HDL cholesterol (P < 0.05; Table 2). Due to the inverse
relationship between the Lp(a) plasma concentration and the
molecular weight of apo(a), the latter showed only a significant
correlation when the Lp(a) plasma concentration was excluded
from the model. In this case it contributed mostly to the amount
of LDL-unbound apo(a) (P < 0.001).
We investigated the amount of LDL-unbound apo(a) in two
further treatment modes used for ESRD: the first group included
20 patients treated by CAPD, and in the second group we
prospectively followed the influence of successful renal transplan-
tation in 19 hemodialysis patients. Lp(a) and the absolute amount
of LDL-unbound apo(a) were higher in CAPD patients when
compared to the entire group of 185 hemodialysis patients (43.8
48.9 mg/dI vs. 25.2 28.0 mgldl and 2.14 2.86 mg/dl vs. 1.22
1.55 mgldl, respectively). This difference did not reach signifi-
cance due to the small number of CAPD patients. The relative
amount of LDL-unbound apo(a), however, was the same in the
two groups (7.5 7.2% vs. 7.3 5.8%). The group of 19
hemodialysis patients undergoing renal transplantation was inves-
tigated immediately before and four weeks after renal transplan-
tation. Lp(a) plasma concentrations decreased significantly from
17.4 17.5 mg/dl to 8.9 10.5 mg/dl (P < 0.001). LDL-unbound
apo(a) decreased from 0.27 0.20 mg/dl to 0.17 0.11 mg/dl
(P < 0.001). Each patient showed a decrease in the absolute
amount of LDL-unbound apo(a) (Fig. 3). The relative amount of
LDL-unbound apo(a) did not change significantly (2.0 1.1 vs.
2.7 2.0%, P > 0.25).
In vitro findings
Since most of the LDL-unbound apo(a) exists as apo(a) frag-
ments, we next investigated whether the uremic plasma condition
itself has an apo(a)-fragment-generating effect. Therefore, we
partially "uremized" plasma samples from seven healthy probands
by adding the same amount of plasma from a hemodialysis patient
with only 0.03 mg/dl of Lp(a) plasma concentration and a plasma
creatinine of 10.2 mg/dl. After incubation for 24 hours at 4°C we
found no shift in the apo(a) isoform pattern (data not shown).
Furthermore, we recovered the same amount of LDL-unbound
apo(a) as in the original plasma samples (Fig. 4). Therefore
"uremization" of plasma samples did not generate a higher
amount of LDL-unbound apo(a).
Finally, we investigated whether differences in the assembly of
Lp(a) exist between hemodialysis patients and controls in vitro.
With these experiments we wanted to address two questions: (1)
Is an impaired assembly of Lp(a) responsible for higher amounts
A Table 2. Results of stepwise regression analysis on the influence of
various variables on the absolute amount of LDL-unbound apo(a)
I
00.
0
0
.0
0
-J
I
00.
C
0
.0C
-Ja
-J
10
8
6
4
2
0
10
8
6
4
2
0
50 100
Lp(a), mg/dI
B
150 200
Trenkwalder et al: LDL-unbound apo(a) in ESRD 1689
of LDL-unbound apo(a) that consequently degrades to apo(a)
fragments? (2) Is an accelerated or more efficient assembly of
apo(a) with LDL responsible for the increased Lp(a) plasma
concentrations in hemodialysis patients? For this reason we
purified LDL from eight hemodialysis patients and eight controls
and incubated this apo(a)-free LDL with human embryonic
kidney cells (293T) stably transfected with an apo(a) expression
vector containing 18 kringle-TV repeats [22]. These cells secrete
only recombinant apo(a) and no lipoproteins. By adding purified
LDL from hemodialysis patients or controls to the medium
containing the cells, Lp(a) was extracellularly assembled (Fig. 5).
There was no difference between patients and controls; both
groups showed a very similar relative amount of assemhled Lp(a)
at each time (Fig. 6). After 60 minutes almost 50% of recombi-
nant apo(a) had formed an Lp(a)-eomplex in both patients and
controls.
DISCUSSION
In the first part of this study we quantified the plasma concen-
trations of LDL-unbound apo(a) in hemodialysis patients and
1 2 3 4 5 6
% LDL-unbound apo(a): original samples
Fig. 4. Influence of uremic plasma condition on the generation of apo(a)-
fragments. Plasma samples from seven healthy probands were partially
"uremized" by adding the same amount of plasma from a hemodialysis
patient with only 0.03 mg/dl Lp(a) plasma concentration and a plasma
creatinine of 10.2 mgldl. After incubation for 24 hours at 4°C the same
amount of LDL-unbound apo(a) was recovered as in the original plasma
samples. r = 0.96; P < 0.005.
controls. This "free" apo(a) was recently shown to exist in healthy
humans, mainly in a fragmented form with a molecular weight
ranging from about 125 to 360 kDa [201. The fragments in a given
individual differ in size by about 25 to 30 kDa, which is the size of
a single K-TV repeat [34]. Furthermore, apo(a) K-TV repeats
containing fragments smaller in size (30 to 215 kDa) have been
detected in human urine [16—18]. Injection of purified plasma
apo(a) fragments into mice resulted in excretion of smaller apo(a)
fragments into urine, which matched the size of human urinary
fragments. These experiments suggested that apo(a) fragments in
human plasma are derived from circulating apo(a) or Lp(a) and
that these fragments are the source of urinary apo(a) fragments
[20]. Recently, however, we were not able to find lower values of
LDL-unbound apo(a) in the renal vein [19], which allows at least
two interpretations: first, the kidney does not clear these frag-
ments; or second, the kidney could be the site of clearance as well
as of production of these fragments. This would result in a similar
amount of LDL-unbound apo(a) in the two vessels although the
kidney extracts apo(a) fragments.
Besides elevated plasma concentrations of Lp(a), in our inves-
tigation we observed increased plasma concentrations of LDL-
unbound apo(a) in hemodialysis patients when compared to
controls, both in absolute as well as in relative terms (Table 1 and
Fig. 1). Tn both groups Lp(a) plasma concentrations showed a
strong positive correlation with the absolute amount of unbound
apo(a) (Fig. 2) and a negative correlation with the relative values.
In particular, subjects with low concentrations of Lp(a) showed a
markedly higher relative amount of LDL-unbound apo(a) than
did those with high Lp(a) concentrations. Most of the Lp(a) assays
1.0
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Fig. 3. Changes of LDL-unbound apo(a) in 19 hemodialysis patients
before and four weeks after successful renal transplantation. Arrows
indicate the mean values of LDL-unbound apo(a) before and after renal
transplantation.
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Fig. 5. In vitro assemb'y of Lp(a). LDL from
eight hemodialysis patients and eight controls
was purified by sequential ultracentrifugation.
Fifty g/ml of these apo(a)-free LDL was
incubated with human embryonic kidney cells
(293T) stably transfected with an apo(a)
expression vector containing 18 kringle-IV
repeats [22]. These cells secrete only
recombinant apo(a) and no lipoproteins. The
relative amount of apo(a) found as assembled
Lp(a) complex was estimated for controls and
hemodialysis patients in relation to the time of
incubation. Data at 0 minutes are not shown,
since at this time simply medium containing
LDL was added to the cells and the purity of
LDL was already confirmed by SDS-PAGE
followed by silver staining (data not shown).
This graphic shows a representative example of
assembly in one hemodialysis patient and one
control.
measure both Lp(a) as well as LDL-unbound apo(a). The higher
values of LDL-unbound apo(a) found in our patients, however,
cannot explain the elevated concentrations of apo(a) immunore-
activity reported in patients with end-stage renal disease [7].
We are aware of the limitations of most of the assays including
ours for quantifying LDL-unbound apo(a). Since our ELISA
protocol uses an antibody that recognizes repetitive epitopes on
the kringle-IV [241 and nothing is known about the structure and
the steric properties of apo(a) fragments, "free" apo(a) values
might be over- or underestimated. The assay employed is never-
theless suitable for investigating differences in these values be-
tween different study groups. Due to the high number of apo(a)
fragments derived from one Lp(a) molecule an overestimation of
LDL-unbound apo(a) can probably be expected. Nonetheless,
these less than 1 mg!dl higher values of LDL-unbound apo(a)
cannot explain the higher values of Lp(a) concentrations mea-
sured in these patients. Otherwise, patients treated by CAPD,
who have markedly higher Lp(a) values than hemodialysis pa-
tients [321, would have extremely high amounts of LDL-unbound
apo(a). This was, however, not the case: CAPD patients had the
same relative amount of LDL-unbound apo(a) as did hemodial-
ysis patients (7.3 5.8% vs. 7.5 7.2%, P = NS).
Multivariate regression analysis revealed that the absolute
amount of LDL-unbound apo(a) was mainly determined by Lp(a)
plasma concentration and patient status (Table 2). Therefore,
hemodialysis patients with elevated Lp(a) levels also have higher
absolute amounts of LDL-unbound apo(a), and these absolute
amounts are even higher in CAPD patients known for their
pronounced elevation of Lp(a) [7, 321. This finding is also
supported by the observation of a decrease in the absolute amount
of LDL-unbound apo(a) following renal transplantation (Fig. 3).
Most probably this decrease was caused by an improvement of
kidney function and not by cyclosporine, as it was recently
suggested for Lp(a) [35] but, however, not confirmed by other
studies in subjects without renal disease receiving cyclosporine
[36—38]. Furthermore, two out of the 19 patients received no
cyclosporine yet nevertheless showed a decrease of LDL-unbound
apo(a).
Since not only the absolute but also the relative amount of these
fragments are elevated in hemodialysis and CAPD patients, we
suggest that the amount of LDL-unbound apo(a) is also deter-
mined by other mechanisms and not simply by the Lp(a) plasma
concentrations. We therefore tried in vitro to perform a "partial
uremization" of plasma samples from healthy subjects simply by
diluting these samples with plasma from a hemodialysis patient
who had almost no Lp(a) (0.03 mgldl). Using the plasma of such
a patient resulted in a partial uremization of plasma of healthy
controls, almost without introducing the effect of additional Lp(a)
particles or apo(a) fragments. It was not possible by this proce-
dure to generate a higher amount of LDL-unbound apo(a) (Fig.
4). We thus conclude that the uremic conditions per se or
unknown factors in uremic plasma arc not responsible for gener-
ating elevated LDL-unhound apo(a) in hemodialysis patients.
We therefore investigated whether the assembly of Lp(a) is
impaired in hemodialysis patients. There is strong evidence that
assembly occurs outside the liver cell or at its surface and from
preformed apo(a) and LDL [39]. It was shown that r-apo(a) from
transiently transfected HepG2 cells was secreted as free recom-
binant apo(a) into the cell medium. No assembled Lp(a) was
found intracellularly [40]. Experiments in transfected Cos-7 cells
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Fig. 6. In vitro assembly of Lp(a). The relative amount of apo(a) found
as assembled Lp(a) complex is shown for controls and hemodialysis
patients in relation to the time of incubation. After 60 minutes almost 50%
of apo(a) had formed an Lp(a)-complex in patients (•) and controls (0).
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incubated with human LDL resulted in an r-apo(a)-LDL complex
resembling human Lp(a). This complex was formed independent
of whether LDL was incubated in the presence of cells or with
conditioned medium only, which suggests that cell structure is not
mandatory for forming an Lp(a) complex [411. It was furthermore
shown that structure and composition of LDL may have an
influence on the formation of an Lp(a) complex. Examples are the
impaired or even abolished assembly in metabolic disorders such
as LCAT-deficiency [421, familial defective apolipoprotein B-100
[43] and abetalipoproteinemia [44]. Since LDL of renal patients
has different chemical and structural properties as compared to
control LDL [45—49], we decided to investigate the ability of LDL
to assemble into an Lp(a) complex with recombinant apo(a).
These experiments clearly showed that the ability of LDL from
hemodialysis patients and controls to assemble Lp(a) did not
differ between these two groups. Therefore, both hypotheses
proposed above can be rejected. First, the higher amounts of
LDL-unbound apo(a) in hemodialysis patients are not caused by
an impaired ability of Lp(a) assembly, and second, the higher
Lp(a) plasma concentrations in patients with end-stage renal
disease cannot be explained by a more efficient assembly of Lp(a)
complexes. However, this does not mean that apo(a) synthesis is
normal in these patients since this study investigated only the
ability and kinetics of the extracellular assembly of r-apo(a) with
LDL. We did not study the kinetic of r-apo(a) production or
secretion. This would require a high reproducibility which was not
possible for technical reasons: we applied a fixed volume of the
medium to the gel. Therefore, the intensity of the bands between
the different times varied depending on the protein concentration
in the small amounts of medium taken at different times. This is
the reason why, for example, the r-apo(a) bands at 30 and 60
minutes in the medium of the control subject in Figure 5 appeared
to be weaker than those at 90 and 120 minutes. We therefore
decided to investigate simply the ability and kinetics of complex
formation. The calculation of this ratio or percentage is not
influenced by the absolute amounts and was therefore highly
reproducible. Consequently, only in vivo turnover studies using
stable isotope technique [50] will be able to clarify whether the
synthesis or catabolism of Lp(a) is disturbed in hemodialysis
patients.
Finally, the role of LDL-unbound apo(a) in the development of
atherosclerotic complications in humans remains to be clarified.
Recent studies in mice transgenic for the human apo(a) gene have
suggested a role of the LDL-unbound apo(a) in the development
of atherosclerosis changes [51]. Some immunohistochemical stud-
ies observed uncomplexed apo(a) in atherosclerotic lesions of the
arterial vessel wall [52, 53]. In ongoing studies we are investigating
whether degradation products of apo(a) in plasma are still or
more atherogenic than intact Lp(a) or apo(a).
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